In a large, UK-based, retrospective study of 2,472 asthma patients, real world evidence showed that initiating or changing to flutiform is associated with:
Data from 618 patients initiated on flutiform, or changed to flutiform from Seretide® Evohaler®, were matched in a 1:3 ratio with data from 1,854 similar patients initiated on, or continuing, Seretide® Evohaler®. Asthma control and healthcare costs were compared over the course of one year.
*Asthma control was defined as having no severe exacerbations during the one-year study period. Severe exacerbations were defined as an unscheduled hospital admission, emergency department or out-of-hours attendance for asthma, an acute course of oral steroids, or a GP consultation for a lower respiratory tract infection.
In a retrospective database study of the real-life effectiveness of flutiform, 88% of patients switched successfully to flutiform from Seretide® Evohaler®.2
Of the 164 patients changing their therapy to flutiform, 88.4% had at least 1 further flutiform prescription 6 months following the change. Change success was defined as ≥70% of patients receiving ≥1 prescriptions of flutiform in the 6 months following therapy change (not including first prescription). flutiform is licensed for asthma maintenance therapy for patients 12 years and older (low and medium strengths), adults (all strengths).